Arcutis Biotherapeutics (NASDAQ:ARQT) just reported results for the first quarter of 2024.
- Arcutis Biotherapeutics reported earnings per share of -32 cents. This was above the analyst estimate for EPS of -73 cents.
- The company reported revenue of $49.57 million.
- This was 237.66% better than the analyst estimate for revenue of $14.68 million.